Wednesday, July 28, 2021

French biopharma major Ipsen expands direct operations to MEA with headquarters in the UAE

Dubai (UAE), 18 July 2021 -Ipsen (Euronext: IPN; ADR: IPSEY), inaugurated its first regional office in the
Middle East and Africa (MEA), headquartered in Dubai, to kickstart direct
operations and bring innovative treatments to serve unmet medical needs
covering oncology, rare diseases and neuroscience in the region.

The
opening of Ipsen’s regional headquarters in the Al Jalila Foundation Building
at Dubai Healthcare City was attended by His Excellency Dr Amin Hussain Al
Amiri, Assistant Undersecretary of Health Regulations Sector at the UAE
Ministry of Health and Prevention (MoHAP), Her Excellency Raja Rabia, Consul
General of France to Dubai and Northern Emirates, Dr Abdulkareem Sultan Al
Olama, CEO of Al Jalila Foundation, Professor Humaid Al Shamsi, President of
the Emirates Oncology Society, representatives of the medical community, and
Ipsen leaders.

His Excellency Dr Amin Hussain Al Amiri said,The UAE has emerged as a global
pharmaceutical hub led by an exceptional healthcare and business
infrastructure, and a strong legislative environment that supports innovative
and international-standard healthcare enterprises. Ipsen
s commitment to investing in the UAE and the
region, and its decision to open its regional headquarters here is a welcome
step that further underlines our nation’s rich legacy of facilitating the
regional expansion of multinational firms. We look forward to path-breaking
therapies by Ipsen that will help the healthcare community further secure the
wellbeing of our communities.

Her
Excellency Raja Rabia, Consul General of France to Dubai and Northern Emirates
said,The United Arab Emirates and France enjoy a strong and long-standing
relationship covering culture, business, education, healthcare and more. Over
the years, French companies have contributed to the economy and gained from the
opportunities offered by the country both at a national level and to expand to
regional markets. We congratulate Ipsen on the opening of their new regional
headquarters in the UAE and look forward to the positive impact this creates on
the lives of patients as we continue to strengthen the friendship between our
nations and build on the strong bilateral relations.

Dr Abdulkareem Sultan Al Olama, CEO of Al
Jalila Foundation, said:
“Ipsen’s decision to open their first regional office in the Middle East
and Africa (MEA) in Dubai is testament to the growing healthcare industry in
the UAE with the pharmaceutical sector being a major player. In Al Jalila
Foundation’s mission to create a medical research innovation hub for the
advancement of science, we are extremely proud that Ipsen chose our building as
a base for their operations to serve patients in the region.”

Vice President of Middle East, Africa and
Maghreb for Ipsen, Matthieu Savarzeix
said, “As a French biopharmaceutical
company with over 90 years of heritage and a global presence in advancing
R&D programs, we have continuously focused on creating exceptional value to
the local communities we serve. We
are dedicated to
improving patients
lives and health
outcomes, and
consistently focus on introducing innovative treatments and breakthrough
medicines that help enhance the quality of life”

Middle East and Africa Specialty Care
Operations Head for Ipsen, Khaled Elrefae added,
The opening of our new office in Dubai is
a milestone for our company. We look forward to building value through our
global innovation in oncology, rare diseases and neuroscience, as we strive to
contribute to the health and well-being of the people of the UAE, and the region,
especially at a time when healthcare is top priority.

The pharmaceutical industry has been a key
focus area for the UAE over the past decade, with the government implementing
strategic and long-term plans to develop and grow the market. Multinational
pharmaceutical companies are leveraging the country’s robust infrastructure,
economic incentives and attractiveness to top talent to manage vast regions. Ipsen’s regional office and headquarters
will help in faster access to innovative treatments for patients with unmet
medical needs.

Addressing
life-threatening and underserved diseases through transformative medicines,
Ipsen’s areas of expertise include Neuroendocrine tumors which is the second
most prevalent gastrointestinal neoplasm after colorectal cancer[1];
prostate cancer, breast cancer, spasticity, and renal and hepatocellular cell
carcinoma among others.

In 2020, Ipsen Group
reported net sales which exceeded 2.5 billion Euros, representing 3% growth in
sales. The company continued to increase R&D investments reaching 15.6% of
net sales and has also made significant strides in building a rare disease
franchise for the next decade.

Related Posts

Comments

Stay Connected

22,044FansLike
0FollowersFollow
0SubscribersSubscribe

Recent Stories